Study on MK-2010 and Sacituzumab Tirumotecan for Treating Advanced Solid Tumors

Inclusion Criteria

• Have a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• If living with HIV, the virus must be well-controlled with medication.
• If positive for hepatitis B, the virus must be undetectable and treated for at least 4 weeks.
• If previously infected with hepatitis C, the virus must be undetectable.
• Must have adequate organ function.

Exclusion Criteria

• Have received any cancer treatment within 4 weeks or 5 half-lives before starting the study.
• Have had local cancer treatments within 2 weeks before the study or have ongoing side effects from such treatments.
• Are currently taking blood thinners.
• Stopped previous immunotherapy due to severe side effects.
• Have an immune system deficiency or are on long-term steroid or immunosuppressive therapy.
• Have another progressing cancer or one that needed treatment in the last 2 years.
• Have cancer that has spread to the brain or spinal cord.
• Have an active autoimmune disease needing treatment in the last 2 years.
• Have a history of lung inflammation needing steroids or current lung issues.
• Have ongoing mouth sores or inflammation.
• Have HIV with a history of certain related diseases.
• Have severe liver conditions or complications.
• Have a history of certain brain conditions or seizures.
• Have severe eye conditions affecting healing.
• Have had a stem cell or organ transplant.
• Have not fully recovered from major surgery or have surgical complications.
• Have had significant bleeding in the last 4 weeks.
• Have had serious bleeding events in the last 3 months.
• Have fluid buildup around the lungs, heart, or abdomen needing drainage.
• Have a history of heart inflammation or disease.